3-amino-2-(4-cyanophenylamino)-6-(2,6-dimethyl-4-cyanophenoxy)-pyridine | 1191279-79-4

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 3-amino-2-(4-cyanophenylamino)-6-(2,6-dimethyl-4-cyanophenoxy)-pyridine
• 英文别名: 4-[[5-Amino-6-(4-cyanoanilino)-2-pyridyl]oxy]-3,5-dimethyl-benzonitrile；4-[5-amino-6-(4-cyanoanilino)pyridin-2-yl]oxy-3,5-dimethylbenzonitrile
• CAS: 1191279-79-4
• 化学式: C₂₁H₁₇N₅O
• 分子量: 355.399
• InChiKey: BGCIQJZDGQMCIR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  27
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  108
• 氢给体数：
  2
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  2-(4-cyanophenylamino)-6-(2,6-dimethyl-4-cyanophenoxy)-3-nitropyridine 在 palladium 10% on activated carbon 作用下， 以 异丙醇 、 环己烯 为溶剂， 反应 5.0h， 以66%的产率得到3-amino-2-(4-cyanophenylamino)-6-(2,6-dimethyl-4-cyanophenoxy)-pyridine
  参考文献：
  名称：

  2-(4-SUBSTITUTED PHENYLAMINO) POLYSUBSTITUTED PYRIDINE COMPOUNDS AS INHIBITORS OF NON-NUCLEOSIDE HIV REVERSE TRANSCRIPTASE, PREPARATION METHODS AND USES THEREOF

  摘要：

  这项发明涉及作为非核苷类HIV逆转录酶抑制剂的2-(4-取代苯胺基)多取代吡啶化合物，以及其制备方法和用途。具体而言，该发明涉及具有式I或其药学上可接受的盐的化合物，其中R1、R2、R3、R4、R5、R6、R7和X如描述中所定义。该发明的式I化合物是一种具有新骨架结构的抗HIV活性化合物。

  公开号：

  US20120053213A1

文献信息

• 2-(4-SUBSTITUTED PHENYLAMINO) POLYSUBSTITUTED PYRIDINE COMPOUNDS AS INHIBITORS OF NON-NUCLEOSIDE HIV REVERSE TRANSCRIPTASE, PREPARATION METHODS AND USES THEREOF
  申请人：Xie Lan

  公开号：US20120053213A1

  公开（公告）日：2012-03-01

  The invention relates to 2-(4-Substituted phenylamino) polysubstituted pyridine compounds as inhibitors of non-nucleoside HIV reverse transcriptase, preparation methods and uses thereof. Specifically, the invention relates to compounds of formula I or the pharmaceutically acceptable salts thereof, wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 and X are as defined in the description. The compounds of formula I of the invention are a type of anti-HIV active compounds having new backbone structure.

  这项发明涉及作为非核苷类HIV逆转录酶抑制剂的2-(4-取代苯胺基)多取代吡啶化合物，以及其制备方法和用途。具体而言，该发明涉及具有式I或其药学上可接受的盐的化合物，其中R1、R2、R3、R4、R5、R6、R7和X如描述中所定义。该发明的式I化合物是一种具有新骨架结构的抗HIV活性化合物。
• THE 2-(4-SUBSTITUTED PHENYLAMINO) POLYSUBSTITUTED PYRIDINE COMPOUNDS AS THE INHIBITORS OF NON-NUCLEOSIDE HIV REVERSE TRANSCRIPTASE, PRAPARATION METHODS AND USES THEREOF
  申请人：Institute Of Pharmacology And Toxicology Academy Of Military Medical Sciences P.L.A. China

  公开号：EP2351739A1

  公开（公告）日：2011-08-03

  The invention relates to 2-(4-Substituted phenylamino) polysubstituted pyridine compounds as inhibitors of non-nucleoside HIV reverse transcriptase, preparation methods and uses thereof. Specifically, the invention relates to compounds of formula I or the pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, R5, R6, R7 and X are as defined in the description. The compounds of formula I of the invention are a type of anti-HIV active compounds having new backbone structure.

  本发明涉及作为非核苷类HIV逆转录酶抑制剂的2-(4-取代苯基氨基)多取代吡啶化合物及其制备方法和用途。具体而言，本发明涉及式 I 的化合物或其药学上可接受的盐类，其中 R1、R2、R3、R4、R5、R6、R7 和 X 如描述中所定义。本发明的式 I 化合物是一种具有新型骨架结构的抗 HIV 活性化合物。
• 2-(4-SUBSTITUTED PHENYLAMINO) POLYSUBSTITUTED PYRIDINE COMPOUNDS AS THE INHIBITORS OF NON-NUCLEOSIDE HIV REVERSE TRANSCRIPTASE, PRAPARATION METHODS AND USES THEREOF
  申请人：Institute Of Pharmacology And Toxicology Academy Of Military Medical Sciences P.L.A. China

  公开号：EP2351739B1

  公开（公告）日：2013-07-31
• US8933106B2
  申请人：——

  公开号：US8933106B2

  公开（公告）日：2015-01-13
• Discovery of diarylpyridine derivatives as novel non-nucleoside HIV-1 reverse transcriptase inhibitors
  作者：Xingtao Tian、Bingjie Qin、Hong Lu、Weihong Lai、Shibo Jiang、Kuo-Hsiung Lee、Chin Ho Chen、Lan Xie

  DOI：10.1016/j.bmcl.2009.07.080

  日期：2009.9

  Two series (4 and 5) of diarylpyridine derivatives were designed, synthesized, and evaluated for anti-HIV-1 activity. The most promising compound, 5e, inhibited HIV-1 IIIB, NL4-3, and RTMDR1 with low nanomolar EC50 values and selectivity indexes of >10,000. The results of this study indicate that diarylpyridine can be used as a novel scaffold to derive a new class of potent NNRTIs, active against both wild-type and drug-resistant HIV-1 strains. (C) 2009 Elsevier Ltd. All rights reserved.